{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:18:03Z","timestamp":1790716683239,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijgc.2026.104990","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:43:46Z","timestamp":1787438626000},"page":"104990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alignment between patient-reported outcomes and clinician-reported adverse events in gynecologic oncology trials: a scoping review"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0026-9548","authenticated-orcid":false,"given":"Daniela","family":"Krepper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9762","authenticated-orcid":false,"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3563-1825","authenticated-orcid":false,"given":"Reyes","family":"Oliver-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0674-9405","authenticated-orcid":false,"given":"Johanna WM.","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sztankay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Giesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-7517","authenticated-orcid":false,"given":"Jens","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2026.104990_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijgc.2026.104990_bib2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","article-title":"Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events","volume":"30","author":"Madariaga","year":"2020","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ijgc.2026.104990_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/cancers14020441","article-title":"Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of Clinical Trials","volume":"14","author":"Schmidt","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ijgc.2026.104990_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102117","article-title":"Safety of antibody-drug conjugates in gynecologic cancers: current evidence and management approaches","volume":"35","author":"Ciliberti","year":"2025","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ijgc.2026.104990_bib5","series-title":"Core Patient-Reported Outcomes in Cancer Clinical Trials: Guidance for Industry","year":"2024"},{"key":"10.1016\/j.ijgc.2026.104990_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005883","article-title":"Proactive assessment of patient reported outcomes in ovarian cancer studies: a systematic review and call for action in future studies","volume":"36","author":"Madariaga","year":"2026","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ijgc.2026.104990_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ijgc-2022-003727","article-title":"Outcomes and endpoints of relevance in gynecologic cancer clinical trials","volume":"33","author":"Madariaga","year":"2023","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ijgc.2026.104990_bib8","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.104990_bib9","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S1470-2045(24)00451-0","article-title":"Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials","volume":"26","author":"Gyawali","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.104990_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2024.02.003","article-title":"High grade adverse event reporting and enrolment in gynecologic oncology clinical trials","volume":"185","author":"Madariaga","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104990_bib11","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/s41416-022-01926-z","article-title":"Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE","volume":"127","author":"Watson","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijgc.2026.104990_bib12","first-page":"3669","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.ijgc.2026.104990_bib13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The Missing Voice of Patients in Drug-Safety Reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijgc.2026.104990_bib14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijgc.2026.104990_bib15","series-title":"DistillerSR. DistillerSR Inc","year":"2025"},{"key":"10.1016\/j.ijgc.2026.104990_bib16","series-title":"IBM SPSS Statistics for Windows","year":"2022"},{"key":"10.1016\/j.ijgc.2026.104990_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1634\/theoncologist.2017-0297","article-title":"A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve","volume":"23","author":"Wilson","year":"2018","journal-title":"The Oncologist"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104990_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.46439\/reproductivemed.1.004","article-title":"A scoping review of outcome measures in ovarian cancer clinical trials","volume":"1","author":"Wang","year":"2024","journal-title":"J Clin Exp Reprod Med"},{"key":"10.1016\/j.ijgc.2026.104990_bib19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijgc.2026.104990_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104345","article-title":"Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review","volume":"197","author":"Roets","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijgc.2026.104990_bib21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/ejh.70002","article-title":"Quality of Patient-Reported Outcomes in Multiple Myeloma Randomized Controlled Trial Protocols and Publications According to the SPIRIT - PRO and CONSORT - PRO guidelines : A Systematic Review","volume":"115","author":"Shah","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ijgc.2026.104990_bib22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104990_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115392","article-title":"Flexibility in patient-reported outcome and health-related quality of life measurement: The EORTC Quality of Life Group measurement strategy","volume":"220","author":"Piccinin","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2026.104990_bib24","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/S1470-2045(22)00654-4","article-title":"Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group","volume":"24","author":"Piccinin","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.104990_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijgc.2026.104990_bib26","article-title":"EORTC Quality of Life Group Item Library","year":"2026","journal-title":"EORTC Quality of Life"},{"key":"10.1016\/j.ijgc.2026.104990_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2022.08.006","volume":"167","author":"Madariaga","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104990_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jamaophthalmol.2025.3159","article-title":"Multicenter Interspecialty Consensus on Experimental Oncology Drug\u2013Related Ocular Adverse Event Reporting","volume":"144","author":"Pasricha","year":"2026","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ijgc.2026.104990_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/PROM.S297301","article-title":"Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice","volume":"14","author":"Campbell","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.ijgc.2026.104990_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(25)00679-5","article-title":"Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial","volume":"27","author":"Wintner","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.104990_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115333","article-title":"Exploring the integration of patient-reported outcome measures in clinical practice: A cross-sectional survey of EORTC healthcare professionals","volume":"220","author":"Lehmann","year":"2025","journal-title":"Eur J Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26005219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26005219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:40:37Z","timestamp":1790714437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26005219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S1048891X26005219"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104990","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alignment between patient-reported outcomes and clinician-reported adverse events in gynecologic oncology trials: a scoping review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104990"}}